Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
After two years of dedicated and persistent advocacy by ADI, dementia will, for the first time, be formally recognised within the new UN Political Declaration on noncommunicable diseases (NCDs) and mental health, as a leading NCD.
The 78th World Health Assembly has been a whirlwind week for ADI as, after 18-months of advocacy, the World Health Assembly has agreed to extend the Global Action Plan on the Public Health Response to Dementia by 6-years, to 2031.
ADI welcomes the approval of Peru’s National Plan for the Prevention and Treatment of Alzheimer’s Disease and Other Dementias 2026–2028, officially validated by the Ministry of Health through a newly published ministerial resolution. This landmark decision places dementia firmly on Peru’s national health agenda and opens the door to implementation after years of dedicated advocacy from civil society, academia, and key partners.
November 2025 saw a plethora of activity across the European region. From engagements in Ibiza, Reykjavík and Manchester, UK. ADI took part in key events with its members throughout the region to promote greater awareness and activity, towards addressing the growing burden of dementia.
From Switzerland to Italy, ADI has taken part in key engagements on the European continent that convened industry leaders, clinicians, specialists, researchers, regulators, policymakers, advocates, people living with dementia and their carers to bring new insights and strategies to light.
On 13 August, Argentina’s Health and Budget Committees approved the Dementia Bill, marking a major step towards the country’s first National Dementia Plan. Congressman and neuroscientist Facundo Manes urged the government to allocate funding for the law, which now moves to the full Chamber of Deputies before reaching the Senate. ADI welcomes this development as Argentina advances towards making dementia a national health priority.
This month, ADI’s Regional Director for the Asia Pacific, DY Suharya, partook in a number of important meetings and events both in Lyon, France at the WHO Academy, and in Hanoi, Vietnam, alongside Vietnam International Organisation for Better Ageing (VIOBA), who are currently partaking in ADI’s Membership Development Programme.
As part of ADI's ongoing regional commitment to dementia policy, Diego Aguilar, Regional Director for the Americas, completed a high-impact country visit to Mexico that combined academic engagement, civil society coordination, and high-level government and industry dialogue.
This announcement reverses an earlier recommendation made by the EMA regarding donanemab as a treatment for the treatment of early symptomatic Alzheimer's disease in adults.
The National Institute for Health and Care Excellence (NICE) has concluded that the benefits from two treatments for early Alzheimer's Disease, donanemab and lecanemab, remain too small to justify the additional cost. Consequently, free access to these Alzheimer's treatments will not be provided in the UK.